Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
GMAB has added 7% on the week to DKK 2,482, its strongest weekly move in months, as the market digests Wednesday's Q3 results with more enthusiasm than its cautious pre-earnings positioning might have suggested.
The lending market was already telling this story before the print. As noted in the earnings preview published yesterday, borrow availability has been extraordinarily loose. That remains the case after the release. Availability is running at roughly 5,088%, meaning there are more than 50 shares available to lend for every one currently borrowed. The 52-week tightest reading was in early September, when that ratio compressed to around 2,196%. Even at that tighter point, short sellers were not meaningfully present. Cost to borrow is essentially unchanged at 0.71%, down slightly on the week and barely registering as a cost for anyone minded to short the stock. The borrow market is sending one clear message: there is no active short campaign here, and there was not one heading in. The short score of 33 out of 100, climbing slightly through the week, is consistent with a stock that shorts largely ignore.
The Street's view is constructive and has not wavered around the print. Twelve analysts carry a buy rating with no dissenting voices recorded in the current data. The valuation has re-rated alongside the price. The P/E has moved to just over 24x, up roughly 2.7 points over the past month, and price-to-book is now at 3.2x, also expanding over the same period. EV/EBITDA is close to 14.8x. On factor scores, EPS momentum sits in the 81st percentile on both 30-day and 90-day measures, and the short score rank of 75 reflects just how little short-side pressure exists relative to peers. The EPS surprise factor is a softer point, ranking in only the 12th percentile, which means the company's history of beating estimates is not the foundation of the bull case. The bull case rests more on pipeline execution and the durability of its antibody platform than on consensus-beating quarterly prints.
Institutional ownership adds a layer of stability to the register. Orbis Investment Management holds 7.2% of shares, making it the largest disclosed holder. BlackRock, which added 62,000 shares through to the end of September, holds just under 7%. Darwin Global Management carries a notable position of 5.3%, having added more than 3.5 million shares in its most recent disclosure, the largest single reported change among the top holders. AllianceBernstein and Paradigm Biocapital each added meaningfully over the past quarter as well. Norges Bank trimmed its position, but remains a holder of roughly 1.3% of shares. The insider picture is quiet. The most recent open-market transactions on record are small board-level sales from May, with the bulk of the recent activity consisting of standard compensation grants to executives in April.
Among correlated peers, the week looked notably different. GILD fell 4.7%, VSTM dropped 2.1%, and ORIC was the worst performer in the group, down more than 10%. VRDN lost nearly 9%. Against that backdrop, Genmab's 7% gain stands out as a genuine divergence rather than a rising-tide move. The next earnings event is scheduled for November 5, 29 days away, and the market's response to Wednesday's numbers will set the tone for how the stock is positioned heading into that second print.
See the live data behind this article on ORTEX.
Open GMAB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
